KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Current Liabilities: 2018-2024

Historic Total Current Liabilities for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $49.4 million.

  • Castle Biosciences' Total Current Liabilities rose 24.86% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 24.86%. This contributed to the annual value of $49.4 million for FY2024, which is 3.62% up from last year.
  • According to the latest figures from FY2024, Castle Biosciences' Total Current Liabilities is $49.4 million, which was up 3.62% from $47.7 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Total Current Liabilities peaked at $49.4 million during FY2024, and registered a low of $20.9 million during FY2020.
  • Over the past 3 years, Castle Biosciences' median Total Current Liabilities value was $47.7 million (recorded in 2023), while the average stood at $44.4 million.
  • Data for Castle Biosciences' Total Current Liabilities shows a peak YoY surged of 45.17% (in 2022) over the last 5 years.
  • Over the past 5 years, Castle Biosciences' Total Current Liabilities (Yearly) stood at $20.9 million in 2020, then increased by 19.21% to $24.9 million in 2021, then skyrocketed by 45.17% to $36.1 million in 2022, then spiked by 31.94% to $47.7 million in 2023, then grew by 3.62% to $49.4 million in 2024.